Skip to main
BSX

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 50%
Buy 45%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific is facing some short-term challenges due to slower sales of its WATCHMAN product, but its broad and innovative product portfolio as well as strong revenue from other segments should drive sustainable growth in the long run. The company's plans for expansion and cost reduction should also support earnings growth. Some risks include lower-than-expected sales and loss of market share to competitors. However, we maintain a positive outlook for the company's stock with a Buy rating based on its strong financial metrics and potential for future growth.

Bears say

Boston Scientific is experiencing numerous headwinds, forecasting WATCHMAN sales is difficult due to recent clinical trials, reimbursement changes, and physician concerns. The company's reported Q1 revenue beat was due to management's conservative assumptions, and overall organic growth of ~6% in 2027 and 2028 is expected, warranting a 16.0x P/E multiple. Despite this, recent product weakness and lowered guidance have resulted in a negative near-term sentiment for the company.

Boston Scientific (BSX) has been analyzed by 22 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 45% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 22 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Aug 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.91, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.91, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.